TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06224660: Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

Sponsor: Sardocor Corp. · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$1,085,620

Rescue Site Savings

+$700,400

Unlock Full NCT06224660 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06224660 Rescue Dossier →